Best Option Healthcare Puerto Rico LLC

Best Option Healthcare Puerto Rico LLC was paid $41.49M by Medicaid between Jan 2018 and Dec 2024, across 52 billing codes. Its largest line is S9097, Home visit for wound care — 21% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	21,843	$6.05M
2019	38,833	$13.95M
2020	37,533	$3.61M
2021	36,581	$3.58M
2022	38,359	$3.62M
2023	47,466	$4.32M
2024incomplete	58,195	$6.35M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
S9097	Home visit for wound care	21%	111,089	13,148	$8.69M
97602		15%	72,204	7,370	$6.29M
J9035	Injection, bevacizumab, 10 mg	13%	1,317	655	$5.44M
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	8.8%	842	507	$3.67M
T1030	Nursing care, in the home, by registered nurse, per diem	6.1%	23,089	5,504	$2.54M
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	5.4%	20,024	2,102	$2.24M
J9299	Injection, nivolumab, 1 mg	5.4%	628	281	$2.24M
J9306	Injection, pertuzumab, 1 mg	4.3%	417	263	$1.78M
J9271	Injection, pembrolizumab, 1 mg	2.7%	266	206	$1.13M
J9312	Injection, rituximab, 10 mg	2.7%	276	162	$1.10M
E2402	Negative pressure wound therapy electrical pump, stationary or portable	2.5%	1,804	665	$1.06M
S9494	Home infusion therapy, antibiotic, antiviral, or antifungal therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code with home infusion codes for hourly dosing schedules s9497-s9504)	2.5%	10,692	3,550	$1.03M

40 more codes

J1335	Injection, ertapenem sodium, 500 mg	2.0%	1,648	$820K
S9131	Physical therapy; in the home, per diem	1.7%	6,438	$723K
J9395	Injection, fulvestrant, 25 mg	1.2%	311	$482K
T1001	Nursing assessment / evaluation	1.0%	6,153	$426K
J9310	Injection, rituximab, 100 mg	<1%	77	$380K
J0878	Injection, daptomycin, 1 mg	<1%	564	$302K
J0897	Injection, denosumab, 1 mg	<1%	114	$203K
J9070	Cyclophosphamide, 100 mg	<1%	478	$197K
J0640	Injection, leucovorin calcium, per 50 mg	<1%	1,298	$78K
J9263	Injection, oxaliplatin, 0.5 mg	<1%	738	$70K
S9129	Occupational therapy, in the home, per diem	<1%	602	$69K
J3370	Injection, vancomycin hcl, 500 mg	<1%	652	$67K
J3489	Injection, zoledronic acid, 1 mg	<1%	686	$59K
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	<1%	463	$57K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	1,058	$48K
J9171	Injection, docetaxel, 1 mg	<1%	454	$47K
G0157	Services performed by a qualified physical therapist assistant in the home health or hospice setting, each 15 minutes	<1%	444	$33K
99600	Unlisted home visit service or procedure	<1%	480	$31K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	242	$28K
J9267	Injection, paclitaxel, 1 mg	<1%	932	$26K
J9045	Injection, carboplatin, 50 mg	<1%	778	$23K
J9190	Injection, fluorouracil, 500 mg	<1%	1,841	$21K
J0692	Injection, cefepime hydrochloride, 500 mg	<1%	197	$18K
J2185	Injection, meropenem, 100 mg	<1%	64	$13K
S9379	Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	<1%	289	$11K
J9000	Injection, doxorubicin hydrochloride, 10 mg	<1%	423	$10K
J2543	Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)	<1%	64	$9K
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	<1%	68	$8K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	3,143	$6K
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	<1%	39	$4K
J9201	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg	<1%	91	$4K
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	<1%	53	$4K
J9206	Injection, irinotecan, 20 mg	<1%	78	$3K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	<1%	17	$1K
97597		<1%	4,508	$1K
J9060	Injection, cisplatin, powder or solution, 10 mg	<1%	22	$452.40
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	320	$449.71
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	299	$323.39
S0028	Injection, famotidine, 20 mg	<1%	23	$16.19
99341		0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMARK, JUDITH (EXECUTIVE DIRECTOR)

Parent organizationBOH HOLDINGS LLC